JP2015506955A - がんを治療する方法 - Google Patents

がんを治療する方法 Download PDF

Info

Publication number
JP2015506955A
JP2015506955A JP2014555195A JP2014555195A JP2015506955A JP 2015506955 A JP2015506955 A JP 2015506955A JP 2014555195 A JP2014555195 A JP 2014555195A JP 2014555195 A JP2014555195 A JP 2014555195A JP 2015506955 A JP2015506955 A JP 2015506955A
Authority
JP
Japan
Prior art keywords
patient
cancer
polymorphism
genotype
single nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014555195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015506955A5 (enExample
Inventor
コリン、エフ．スプラッグス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Cork Ltd
Original Assignee
SmithKline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Cork Ltd filed Critical SmithKline Beecham Cork Ltd
Publication of JP2015506955A publication Critical patent/JP2015506955A/ja
Publication of JP2015506955A5 publication Critical patent/JP2015506955A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014555195A 2012-01-31 2013-01-31 がんを治療する方法 Pending JP2015506955A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261592893P 2012-01-31 2012-01-31
US61/592,893 2012-01-31
US201261654733P 2012-06-01 2012-06-01
US61/654,733 2012-06-01
PCT/EP2013/051865 WO2013113796A1 (en) 2012-01-31 2013-01-31 Method of treating cancer

Publications (2)

Publication Number Publication Date
JP2015506955A true JP2015506955A (ja) 2015-03-05
JP2015506955A5 JP2015506955A5 (enExample) 2016-03-24

Family

ID=47714037

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014555195A Pending JP2015506955A (ja) 2012-01-31 2013-01-31 がんを治療する方法

Country Status (11)

Country Link
US (1) US20150023953A1 (enExample)
EP (2) EP2809805A1 (enExample)
JP (1) JP2015506955A (enExample)
KR (1) KR20140117644A (enExample)
CN (1) CN104204226A (enExample)
AU (1) AU2013214254B2 (enExample)
BR (1) BR112014019034A8 (enExample)
CA (1) CA2863287A1 (enExample)
IN (1) IN2014DN06127A (enExample)
RU (1) RU2014135224A (enExample)
WO (1) WO2013113796A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023513013A (ja) * 2020-01-29 2023-03-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｎｒｇ１融合体を有するがんの治療のためのキナゾリンベースのチロシンキナーゼインヒビターの使用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109504743A (zh) * 2017-09-13 2019-03-22 复旦大学附属华山医院 阿帕替尼有效生物标志物vegfr-2基因检测试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008088861A2 (en) * 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual tki therapy
WO2008128233A1 (en) * 2007-04-15 2008-10-23 University Of Chicago Methods and compositions concerning the vegfr-2 gene (kinase domain receptor, kdr)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5871918A (en) 1996-06-20 1999-02-16 The University Of North Carolina At Chapel Hill Electrochemical detection of nucleic acid hybridization
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
WO1997040462A2 (en) 1996-04-19 1997-10-30 Spectra Biomedical, Inc. Correlating polymorphic forms with multiple phenotypes
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GEP20104998B (en) 1999-06-25 2010-06-10 Genentech Inc Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer
AU7307101A (en) 2000-06-30 2002-01-14 Glaxo Group Ltd Quinazoline ditosylate salt compounds
WO2007095038A2 (en) * 2006-02-09 2007-08-23 Novartis Ag Mutations and polymorphisms of erbb2
US20100104583A1 (en) * 2007-01-18 2010-04-29 University Of Southern California Gene Polymorphisms in VEGF and VEGF Receptor 2 as Markers for Cancer Therapy
EP1980626A1 (en) * 2007-04-13 2008-10-15 Het Nederlands Kanker Instituut Involvement of lipid kinase, and signal transduction pathway comprising said lipid kinase, in resistance to HER2-targeting therapy
SG178439A1 (en) * 2009-08-21 2012-04-27 Smithkline Beecham Cork Ltd Method of treating cancer
WO2011060380A1 (en) * 2009-11-14 2011-05-19 The Regents Of The University Of California Pik3ca mutation status and sash1 expression predicts synergy between lapatinib and an akt inhibitor in her2 positive breast cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008088861A2 (en) * 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual tki therapy
WO2008128233A1 (en) * 2007-04-15 2008-10-23 University Of Chicago Methods and compositions concerning the vegfr-2 gene (kinase domain receptor, kdr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023513013A (ja) * 2020-01-29 2023-03-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｎｒｇ１融合体を有するがんの治療のためのキナゾリンベースのチロシンキナーゼインヒビターの使用
JP7734139B2 (ja) 2020-01-29 2025-09-04 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｎｒｇ１融合体を有するがんの治療のためのキナゾリンベースのチロシンキナーゼインヒビターの使用

Also Published As

Publication number Publication date
EP3045543A3 (en) 2016-10-12
CA2863287A1 (en) 2013-08-08
BR112014019034A8 (pt) 2017-07-11
US20150023953A1 (en) 2015-01-22
RU2014135224A (ru) 2016-03-27
IN2014DN06127A (enExample) 2015-08-14
EP2809805A1 (en) 2014-12-10
CN104204226A (zh) 2014-12-10
KR20140117644A (ko) 2014-10-07
AU2013214254B2 (en) 2016-04-21
EP3045543A2 (en) 2016-07-20
AU2013214254A1 (en) 2014-08-14
BR112014019034A2 (enExample) 2017-06-20
WO2013113796A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
US9730925B2 (en) Methods of treating cancer
US20170105997A1 (en) Methods of treating cancer
US10004742B2 (en) Method of treating cancer
AU2012275315B2 (en) Method of administration and treatment
AU2013214254B2 (en) Method of treating cancer

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20150626

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150717

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20151013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161011

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170509